Konark Gupta

Are you seeing any implications whatsoever direct or indirect from the CDL regulations that are going through in the U.S. right now?

if you can talk about the underlying business, how is it performing from a profitability and return standpoint?

How much contribution in terms of revenue have you embedded in the guidance for the full year

can you update us where and what agreements are left right now

you're not assuming the credits for this year. And if so, they come through, what is a realistic set of assumptions there

how should we think about the sensitivity to your earnings from that

where do you see the shedding kind of maybe slowing it down substantially? Is it still more like a second half story or more of a 2027 now

do you think the top end of the guidance range for margin, which was, I think, 31% for the full year, do you think that still is obtainable

How should we think about the growth cadence for the year by quarter

What are you seeing now based on the book that you are left with? What kind of basket of commodity prices you're looking at heading into Q4 and early '26

your SG&A intensity at Healthcare, if I look at the gap versus the Legacy Business, I think it stood at 10 points in Q3

How do you see the bridge to the full $250 million synergy you expect over the next 3 years or 2 years

I'm just wondering if there is a domino effect you would expect from these things in that market

SG&A improved by 70 bps sequentially, but these Stericycle margin itself was up only 20 bps from Q4. Is there any puts and takes behind the gap

should we follow the seasonal pattern we saw last year in revenue? Or we should see some sort of abnormal seasonality

Can you help us understand how are you kind of tackling that situation and how much of that ERP cutover is baked into your expectations

how do you guys envision the growth in that business, obviously, including synergies over the next two years, three years